Tumour regression grading in patients with residual rectal cancer after preoperative chemoradiation

Abstract Background and purpose To explore the utility of tumour regression grading (TRG, the amount of residual tumour cells in relation to extension of fibrosis) after chemoradiation of rectal cancer. Materials and methods Of 131 patients who received preoperative chemoradiation in the frame of th...

Full description

Saved in:
Bibliographic Details
Published in:Radiotherapy and oncology 2010-06, Vol.95 (3), p.298-302
Main Authors: Bujko, Krzysztof, Kolodziejczyk, Milena, Nasierowska-Guttmejer, Anna, Michalski, Wojciech, Kepka, Lucyna, Chmielik, Ewa, Wojnar, Andrzej, Chwalinski, Maciej
Format: Article
Language:English
Subjects:
Adult
Aged
Combined Modality Therapy
Disease-Free Survival
Female
Hematology, Oncology and Palliative Medicine
Humans
Male
Middle Aged
Preoperative chemoradiation
Prognosis
Rectal cancer
Rectal Neoplasms - mortality
Rectal Neoplasms - pathology
Rectal Neoplasms - therapy
Tumour regression grading
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Background and purpose To explore the utility of tumour regression grading (TRG, the amount of residual tumour cells in relation to extension of fibrosis) after chemoradiation of rectal cancer. Materials and methods Of 131 patients who received preoperative chemoradiation in the frame of the randomized trial, pathological complete response (pCR, TRG0), good regression (TRG1), moderate regression (TRG2), and poor regression (TRG3) were recorded in 17%, 31%, 31%, and 22% of patients, respectively. Results The rates of ypN-positive category for TRG0, TRG1, TRG2, and TRG3 groups were 5%, 23%, 45%, and 46%, respectively, p = 0.001. When ypT-category and TRG were evaluated by the logistic regression analysis, only ypT-category remained significant for independent prediction of the risk for mesorectal nodal metastases, p = 0.006. The 4-year (median follow-up) disease-free survival (DFS) for TRG0, TRG1, TRG2, and TRG3 groups were 91%, 67%, 54%, and 47%. When patients with persistent disease (TRG1 vs. TRG2 vs. TRG3) were analyzed separately, TRG had no prognostic value for DFS, p = 0.402. Conclusions TRG in patients with residual cancer had no prognostic value for the incidence of nodal disease and for DFS. Our findings and literature data question the need for the inclusion of TRG assessment into a routine pathological report.
ISSN:0167-8140
1879-0887
DOI:10.1016/j.radonc.2010.04.005